IJE Software logoIJEsoft
ServicesPortfolioPricingAboutCase StudyStackNewsBlogPartnerPH NewsMarketsContactGet in touch
← Back to Philippines Business News
Manila Times Business

AMSilk and Ajinomoto Foods Europe Expand Partnership to Enable Industrial-Scale Production of Silk Proteins

NEURIED, Germany and NESLE, France, July 08, 2026 (GLOBE NEWSWIRE) -- AMSilk, a global leader in biotech produced silk materials, today announced a significant expansion of its partnership with Ajinomoto Foods Europe (AFE), marking a key step in scaling the industrial production of its silk proteins. Building on the collaboration first established in 2023, the two companies have now entered into a long-term manufacturing and supply agreement, enabling the transition from industrial validation to

Context & Analysis

The shift toward biofabricated silk proteins reflects a broader global pivot away from traditional sericulture toward precision fermentation and recombinant biology. Rather than relying on silkworms, companies engineer microorganisms to produce silk fibroin at scale, offering a more predictable supply chain, reduced environmental footprint, and consistent material properties. Ajinomoto’s involvement is strategic; the group has decades of experience in large-scale fermentation for amino acids and food ingredients, making it a natural partner for moving lab-developed proteins into commercial manufacturing.

For Philippine businesses and consumers, this development touches several sectors. The local food and beverage industry increasingly sources novel ingredients to meet rising demand for clean-label, functional, and sustainable products. If biofabricated silk proteins gain regulatory clearance and commercial traction abroad, Filipino manufacturers in cosmetics, nutraceuticals, and specialty textiles could access a more reliable alternative to conventional silk or synthetic polymers. The Food and Drug Administration of the Philippines will play a central role in determining how quickly these ingredients enter the local market, as novel food and cosmetic claims require thorough safety and labeling reviews.

Investors and entrepreneurs should monitor how this technology intersects with the country’s broader biotechnology push. The Department of Science and Technology has been encouraging local startups to develop fermentation capacity and alternative protein platforms, while major conglomerates quietly explore partnerships that could reduce import dependency. What to watch next includes FDA approval timelines for recombinant silk derivatives, potential licensing or distribution deals with Philippine-based FMCG and personal care brands, and whether local manufacturers will invest in downstream processing to capture more value domestically. The real test will be whether industrial-scale production translates into cost-competitive ingredients that can withstand price sensitivity in the Philippine market.

Analysis by IJE Software — original commentary on the story above.

This is an excerpt. Read the full article at the original source:

Source: manilatimes.net

More from Manila Times Business

Amber Group's Accelerator Amber.ac Launches OPC Hackathon in Singapore

1h ago

HSG Laser Unveils TL3 PRO: One Tube Cutter For All Tube Sizes

1h ago

Bisera battles injury, weather to wrest 3-shot lead

1h ago

SM Book Nook activities empower young learners for the new school year

1h ago

Your Daily Briefing

AI business companion — delivered every morning

Markets, PH news, financial insights, and devotionals — curated by AI and sent at 7 AM PHT. Pick your topics below.

Devotionals
Blog Topics
HR & Workforce
Real Estate & Property
News & Markets

1 topic selected